# Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

> **NCT05333276** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** TQB3602 Capsule + AK105 Injection

## Key facts

- **NCT ID:** NCT05333276
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-29
- **Primary completion:** 2023-12
- **Final completion:** 2024-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05333276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05333276, "Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05333276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*